Palomar Holdings, Inc. (NASDAQ:PLMR – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $162.75.
PLMR has been the topic of several analyst reports. JPMorgan Chase & Co. lifted their price objective on Palomar from $150.00 to $167.00 and gave the stock an “overweight” rating in a report on Monday, July 20th. Evercore set a $152.00 price target on Palomar in a research report on Friday, July 10th. Keefe, Bruyette & Woods lifted their price target on Palomar from $166.00 to $167.00 and gave the stock an “outperform” rating in a research note on Monday, August 10th. Zacks Research cut Palomar from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 15th. Finally, Piper Sandler boosted their price objective on Palomar from $132.00 to $165.00 and gave the company an “overweight” rating in a research report on Wednesday, July 15th.
Insiders Place Their Bets
Hedge Funds Weigh In On Palomar
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Kestra Advisory Services LLC purchased a new position in Palomar during the 4th quarter valued at $33,000. Rockefeller Capital Management L.P. raised its holdings in Palomar by 81.5% in the 4th quarter. Rockefeller Capital Management L.P. now owns 294 shares of the company’s stock worth $40,000 after purchasing an additional 132 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of Palomar in the 2nd quarter worth about $43,000. Frazier Financial Advisors LLC purchased a new stake in shares of Palomar in the 4th quarter worth about $54,000. Finally, Parallel Advisors LLC boosted its stake in shares of Palomar by 638.3% during the 1st quarter. Parallel Advisors LLC now owns 443 shares of the company’s stock valued at $53,000 after purchasing an additional 383 shares in the last quarter. Institutional investors own 90.25% of the company’s stock.
Palomar Stock Up 3.0%
Shares of NASDAQ PLMR opened at $136.12 on Tuesday. The stock has a market capitalization of $3.58 billion, a P/E ratio of 18.30 and a beta of 0.39. Palomar has a one year low of $100.81 and a one year high of $147.62. The firm’s 50 day simple moving average is $133.98 and its two-hundred day simple moving average is $124.22. The company has a debt-to-equity ratio of 0.30, a current ratio of 0.50 and a quick ratio of 0.50.
Palomar (NASDAQ:PLMR – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $2.36 earnings per share for the quarter, topping analysts’ consensus estimates of $2.19 by $0.17. The firm had revenue of $314.42 million during the quarter, compared to analyst estimates of $621.52 million. Palomar had a net margin of 18.61% and a return on equity of 23.28%. During the same period in the previous year, the business posted $1.76 EPS. As a group, analysts expect that Palomar will post 9.21 EPS for the current fiscal year.
Palomar Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Wednesday, September 2nd. Shareholders of record on Wednesday, August 19th were given a dividend of $0.45 per share. The ex-dividend date of this dividend was Wednesday, August 19th. This represents a $1.80 annualized dividend and a yield of 1.3%. Palomar’s dividend payout ratio is presently 24.19%.
Palomar Company Profile
Palomar Holdings, Inc (NASDAQ: PLMR) is a specialty insurance holding company focused on providing medical stop-loss coverage and related administrative services to self-funded employer health plans in the United States. The firm operates through two primary business segments—Medical Stop-Loss and Specialty Program Management—to deliver tailored risk protection and comprehensive program administration.
In its Medical Stop-Loss segment, Palomar underwrites excess and aggregate stop-loss policies designed to shield self-insured employers from catastrophic medical claims that exceed pre-determined retention levels.
See Also
- Five stocks we like better than Palomar
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for Palomar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palomar and related companies with MarketBeat.com's FREE daily email newsletter.
